Gilead Sciences (GILD) Offering Possible 12.11% Return Over the Next 28 Calendar Days

Gilead Sciences’s most recent trend suggests a bullish bias. One trading opportunity on Gilead Sciences is a Bull Put Spread using a strike $72.50 short put and a strike $67.50 long put offers a potential 12.11% return on risk over the next 28 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $72.50 by expiration. The full premium credit of $0.54 would be kept by the premium seller. The risk of $4.46 would be incurred if the stock dropped below the $67.50 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Gilead Sciences is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Gilead Sciences is bullish.

The RSI indicator is above 80 which suggests that the stock is in overbought territory.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Gilead Sciences

Cramer’s charts suggest big-name biotech stocks Gilead and Celgene have more room to run
Tue, 17 Jul 2018 22:45:00 +0000
Jim Cramer and technician Bob Lang inspect the charts to see if big-cap biotechnology stocks like Gilead and Celgene could have more room to run.

Sure, these corporate workforces make the big bucks, but do they deserve it?
Tue, 17 Jul 2018 13:25:30 +0000
Who has the most productive workforce in the Bay Area, and how much does each employee rake in per year, on average?

See what the IHS Markit Score report has to say about Gilead Sciences Inc.
Tue, 17 Jul 2018 12:07:58 +0000
Gilead Sciences Inc NASDAQ/NGS:GILD

4 Biggest HIV Drugs of 2024: Which Stocks Are Poised to Profit?
Mon, 16 Jul 2018 12:02:00 +0000
A game of musical chairs is coming to the HIV market.

3 Best Big Pharma Stocks to Buy for the 2nd Half of 2018
Sun, 15 Jul 2018 10:32:00 +0000
Forget what’s happened so far in 2018. These big pharma stocks look like great picks for the rest of the year.

Be Sociable, Share!

Related Posts